A great majority of known VGKCs are located in CNS but only few of them proved the ability to serve as drug targets in disorders like epilepsy (KV7.2-KV7.5), psychosis (KV7), ataxia type I (KV1.1), multiple sclerosis (KV1.3). This evidence concerns the gene KCNQ2 and epilepsy.